Mariette X, et al. - The purpose of this study is to assess the placental transfer of certolizumab pegol (CZP), an Fc-free anti-tumour necrosis factor drug, from CZP-treated pregnant women to their infants. There was no to minimal placental transfer of CZP from mothers to infants, recommending lack of in utero foetal exposure amid the third trimester. These outcomes support the continuation of CZP treatment amid pregnancy when considered necessary.